ObjectiveTo investigate the effect of dendritic cell induced killer cell (DC-CIK) therapy on patients with chronic lymphocytic leukemia and the effect on immune function and platelet parameters. Methods42 patients with chronic lymphocytic leukemia admitted in our hospital from October 2015 to October 2017 were selected. They were randomly divided into the observation group and the control group, with 21 cases in each group. The control group were treated with cyclophosphamide. The observation group were treated with DC-CIK therapy on the basis of the control group. The efficacy, immune function, platelet parameters and incidence of adverse reactions were compared between the two groups. ResultsThe total remission rate (95.24%) in the observation group was significantly higher than that in the control group (66.67%), and the clinical efficacy was significantly better than that in the control group (P＜0.05). After 3 cycles of treatment, the TGF-beta and CD4+CD25+ cells in the observation group were significantly lower than those in the control group, while the Hsp70 and Th1/Th2 were significantly higher than those in the control group (P＜0.05). The levels of PLT, PDW, MPV and PCT in the observation group were significantly higher than those in the control group (P＜0.01). The incidence of adverse reactions in the observation group (9.52%) was significantly lower than that in the control group (42.86%) during the treatment period, and the difference was statistically significant (P＜0.05). ConclusionDC-CIK therapy can effectively improve the clinical symptoms of the patients with chronic lymphocytic leukemia, improve the immune function, make the platelet parameters tend to be normal, and have high safety. It has certain clinical application and promotion value.

无